Cystic fibrosis: newborn screening in America.

Daniel T. Kleven, Christopher R. McCudden, Monte Willis

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Cystic fibrosis is the most common lethal genetic disease in Caucasians, manifesting as progressive lung dysfunction, pancreatic insufficiency, and intestinal disease. CF was traditionally diagnosed clinically, either because of a family history or occurrence of meconium ileus, or as a result of intestinal malabsorption and chronic pulmonary disease. In 1979, it was discovered that immunoreactive trypsinogen was increased in neonatal dried-blood specimens on Guthrie cards, making it possible to screen neonates. During the past decades, survival rates of patients with CF have improved significantly (see Figure 5). To continue this progress, universal newborn screening has been implemented in many states as an addition to the arsenal of therapies and strategies to improve survival. National newborn-screening programs to identify CF patients after birth have been adopted for a number of years in Europe, Australia, and Canada. As expected, many benefits have been seen due to the early identification of CF patients, including improved survival, better lung function and growth with less intensive therapy, and reduced cost of therapy. To date, 37 states in the United States have adopted similar programs, in the hopes of improving CF outcomes. This welcome trend should help improve the lives of CF patients living in America.

Original languageEnglish (US)
JournalMLO: medical laboratory observer
Volume40
Issue number7
StatePublished - Jul 1 2008
Externally publishedYes

Fingerprint

Cystic Fibrosis
Newborn Infant
Hope
Trypsinogen
Exocrine Pancreatic Insufficiency
Intestinal Diseases
Meconium
Pancreatic Diseases
Lung
Inborn Genetic Diseases
Survival
Ileus
Lung Diseases
Canada
Chronic Disease
Therapeutics
Survival Rate
Parturition
Costs and Cost Analysis
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cystic fibrosis : newborn screening in America. / Kleven, Daniel T.; McCudden, Christopher R.; Willis, Monte.

In: MLO: medical laboratory observer, Vol. 40, No. 7, 01.07.2008.

Research output: Contribution to journalReview article

Kleven, Daniel T. ; McCudden, Christopher R. ; Willis, Monte. / Cystic fibrosis : newborn screening in America. In: MLO: medical laboratory observer. 2008 ; Vol. 40, No. 7.
@article{c2780243725a4a4f89949807a7a19d15,
title = "Cystic fibrosis: newborn screening in America.",
abstract = "Cystic fibrosis is the most common lethal genetic disease in Caucasians, manifesting as progressive lung dysfunction, pancreatic insufficiency, and intestinal disease. CF was traditionally diagnosed clinically, either because of a family history or occurrence of meconium ileus, or as a result of intestinal malabsorption and chronic pulmonary disease. In 1979, it was discovered that immunoreactive trypsinogen was increased in neonatal dried-blood specimens on Guthrie cards, making it possible to screen neonates. During the past decades, survival rates of patients with CF have improved significantly (see Figure 5). To continue this progress, universal newborn screening has been implemented in many states as an addition to the arsenal of therapies and strategies to improve survival. National newborn-screening programs to identify CF patients after birth have been adopted for a number of years in Europe, Australia, and Canada. As expected, many benefits have been seen due to the early identification of CF patients, including improved survival, better lung function and growth with less intensive therapy, and reduced cost of therapy. To date, 37 states in the United States have adopted similar programs, in the hopes of improving CF outcomes. This welcome trend should help improve the lives of CF patients living in America.",
author = "Kleven, {Daniel T.} and McCudden, {Christopher R.} and Monte Willis",
year = "2008",
month = "7",
day = "1",
language = "English (US)",
volume = "40",
journal = "Medical Laboratory Observer",
issn = "0580-7247",
publisher = "Nelson Publishing Inc.",
number = "7",

}

TY - JOUR

T1 - Cystic fibrosis

T2 - newborn screening in America.

AU - Kleven, Daniel T.

AU - McCudden, Christopher R.

AU - Willis, Monte

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Cystic fibrosis is the most common lethal genetic disease in Caucasians, manifesting as progressive lung dysfunction, pancreatic insufficiency, and intestinal disease. CF was traditionally diagnosed clinically, either because of a family history or occurrence of meconium ileus, or as a result of intestinal malabsorption and chronic pulmonary disease. In 1979, it was discovered that immunoreactive trypsinogen was increased in neonatal dried-blood specimens on Guthrie cards, making it possible to screen neonates. During the past decades, survival rates of patients with CF have improved significantly (see Figure 5). To continue this progress, universal newborn screening has been implemented in many states as an addition to the arsenal of therapies and strategies to improve survival. National newborn-screening programs to identify CF patients after birth have been adopted for a number of years in Europe, Australia, and Canada. As expected, many benefits have been seen due to the early identification of CF patients, including improved survival, better lung function and growth with less intensive therapy, and reduced cost of therapy. To date, 37 states in the United States have adopted similar programs, in the hopes of improving CF outcomes. This welcome trend should help improve the lives of CF patients living in America.

AB - Cystic fibrosis is the most common lethal genetic disease in Caucasians, manifesting as progressive lung dysfunction, pancreatic insufficiency, and intestinal disease. CF was traditionally diagnosed clinically, either because of a family history or occurrence of meconium ileus, or as a result of intestinal malabsorption and chronic pulmonary disease. In 1979, it was discovered that immunoreactive trypsinogen was increased in neonatal dried-blood specimens on Guthrie cards, making it possible to screen neonates. During the past decades, survival rates of patients with CF have improved significantly (see Figure 5). To continue this progress, universal newborn screening has been implemented in many states as an addition to the arsenal of therapies and strategies to improve survival. National newborn-screening programs to identify CF patients after birth have been adopted for a number of years in Europe, Australia, and Canada. As expected, many benefits have been seen due to the early identification of CF patients, including improved survival, better lung function and growth with less intensive therapy, and reduced cost of therapy. To date, 37 states in the United States have adopted similar programs, in the hopes of improving CF outcomes. This welcome trend should help improve the lives of CF patients living in America.

UR - http://www.scopus.com/inward/record.url?scp=52649118012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649118012&partnerID=8YFLogxK

M3 - Review article

C2 - 18717498

AN - SCOPUS:52649118012

VL - 40

JO - Medical Laboratory Observer

JF - Medical Laboratory Observer

SN - 0580-7247

IS - 7

ER -